TNF/TNFR family members in costimulation of T cell responses

TH Watts - Annu. Rev. Immunol., 2005 - annualreviews.org
▪ Abstract Several members of the tumor necrosis factor receptor (TNFR) family function after
initial T cell activation to sustain T cell responses. This review focuses on CD27, 4-1BB …

From genes to drugs: targeted strategies for melanoma

KT Flaherty, FS Hodi, DE Fisher - Nature Reviews Cancer, 2012 - nature.com
The past decade has revealed that melanoma is comprised of multiple subclasses that can
be categorized on the basis of key features, including the clinical stage of disease, the …

Mitigating the toxic effects of anticancer immunotherapy

TC Gangadhar, RH Vonderheide - Nature reviews Clinical oncology, 2014 - nature.com
Advances in our understanding of the regulatory mechanisms of the immune system have
led to the development of novel approaches for cancer therapy, including inhibition of …

TGF‐β: a mobile purveyor of immune privilege

SM Wahl, J Wen, N Moutsopoulos - Immunological reviews, 2006 - Wiley Online Library
Functionally barricaded immune responses or sites of immune privilege are no longer
considered dependent on specific anatomical considerations, but rather, they can develop in …

Artificial antigen presenting cells and uses therefor

JL Riley, CH June, RH Vonderheide, N Aqui… - US Patent …, 2010 - Google Patents
5,166.320 A 11/1992 Wu et al. 5, 190,878 A 3, 1993 Wilhelm 5,529,921 A 6, 1996 Peterson
et al. 5,827,642 A 10, 1998 Riddell et al. 5,858,358 A 1/1999 June et al. 5,888,807 A 3, 1999 …

[HTML][HTML] The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases

K Wojciechowicz, M Spodzieja, KA Lisowska… - Cellular …, 2022 - Elsevier
Autoimmune diseases constitute a heterogeneous group of disorders with one common
feature–the loss of immune tolerance towards autoantigens. Due to the complexity of the …

Toll-like receptors in tumor immunotherapy

CM Paulos, A Kaiser, C Wrzesinski, CS Hinrichs… - Clinical Cancer …, 2007 - AACR
Lymphodepletion with chemotherapeutic agents or total body irradiation (TBI) before
adoptive transfer of tumor-specific T cells is a critical advancement in the treatment of …

Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways

CF Ware - Immunological reviews, 2008 - Wiley Online Library
Cytokines mediate key communication pathways essential for regulation of immune
responses. Full activation of antigen‐responding lymphocytes requires cooperating signals …

Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells

F Dicker, AP Kater, T Fukuda, TJ Kipps - Blood, 2005 - ashpublications.org
Chronic lymphocytic leukemia (CLL) B cells become sensitive to Fas (CD95)–mediated
apoptosis 3 to 5 days after CD40 ligation. However, CD4+ cytotoxic T lymphocytes (CTLs) …

[HTML][HTML] Cancer immunotherapy using chimeric antigen receptor expressing T-cells: present and future needs of clinical cancer centers

M Gotti, I Defrancesco, M D'Angelo, S Basso… - Frontiers in …, 2020 - frontiersin.org
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents,
designed to selectively attack cancer cells expressing specific antigens, with demonstrated …